GPR3, GPR6 and GPR12 are new molecular targets for CBD: their biological functions and interaction have potential against neurodegenerative diseases
Receptors coupled to G proteins 3, 6 and 12 (GPR3, GPR6 and GPR12) comprise a family of orphan receptors related to cannabinoids. In addition, these new molecular targets are constitutively active. They are described to play an important role in many normal physiological functions. In combination with CBD, they get involved in a variety of pathological conditions, including neurodegenerative diseases.
Receptors to the nearest cannabinoids
Although they are orphans, GPR3, GPR6, and GPR12 are phylogenetically the closest to cannabinoid receptors. We recently discovered that cannabidiol (CBD) non-psychoactive phytocannabinoid is a reverse agonist for GPR3, GPR6 and GPR12.
New therapeutic use against neurodegenerative diseases
This discovery highlights these orphan receptors as potential new molecular targets for CBD. In addition, this provides new mechanisms of action and suggests new therapeutic uses for CBD. Specifically for diseases such as Alzheimer's disease, Parkinson's disease, the cancer et infertility.
In addition, the identification of CBD as a novel inverse agonist for GPR3, GPR6 and GPR12 provides initial chemical scaffolds. With which powerful and effective agents acting on these receptors can be developed. This in order to develop chemical tools to study these orphan receptors and ultimately new therapeutic agents against neurodegenerative diseases. This confirms once again that the cannabis causes neurogenesis, and this time via new molecular targets.